S
Schrodinger
Biotech & Life Sciences · New York City, United States · Founded 1990 · IPO 2020
Computational drug designing for pharmaceutical and biotechnology research MoreLess
Schrödinger operates a cutting-edge computational platform that supports the research initiatives of biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Founded in 1990, the company is dedicated to advancing science and talent to enhance its platform. Schrödinger also engages in both wholly-owned and collaborative drug discovery programs across various therapeutic areas. The business model revolves around providing advanced computational tools and services to its clients, which include a diverse range of organizations in over 70 countries. Revenue is generated through software licensing, collaborative research agreements, and drug discovery partnerships. Keywords: computational platform, biopharmaceutical research, drug discovery, academic institutions, government laboratories, therapeutic areas, software licensing, collaborative research, global reach, science investment.
Talent graph
Schrodinger's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Schrodinger has talent and traffic
team presence
Market sentiment
What the market is saying about Schrodinger
An AI-synthesized read of the highest-engagement posts about Schrodinger on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Schrodinger on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.